KLRS NASDAQ
Kalaris Therapeutics Inc
1W: -7.5%
1M: -30.8%
3M: -41.9%
YTD: -67.5%
1Y: -55.5%
$2.70
-0.15 (-5.26%)
Weekly Expected Move ±5.8%
$2
$3
$3
$3
$3
Overview
News
Chart
Smart Money
Financials
Income Statement
Cash Flow
Balance Sheet
Earnings
Dividends
Analysis
Technicals
Weather
Peers
ESG
Institutions
ETF Exposure
Dark Pool
Short Interest
Supply Chain
Smart Money Score
Moderate
50
Insider+$1.2M
Congress—
ETF Holdings—
Key Statistics
Market Cap$58.9M
52W Range2.51-11.88
Volume235,755
Avg Volume200,564
Beta0.21
Dividend—
Analyst Ratings
Company Info
CEOAndrew Oxtoby
Employees20
SectorHealthcare
IndustryBiotechnology
IPO Date2020-07-30
Websitekalaristx.com
400 Connell Drive
Berkeley Heights, NJ 07922
US
Berkeley Heights, NJ 07922
US
+1 610 550 4220
About Kalaris Therapeutics Inc
Kalaris Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the development and commercialization of treatments for prevalent retinal diseases. It develops TH103, a clinical-stage anti-vascular endothelial growth factor (VEGF) drug for the treatment of neovascular age-related macular degeneration (nAMD), as well as for the treatment of other exudative and neovascular retinal diseases.
Latest News
Kalaris Therapeutics Inc. (NASDAQ:KLRS) Stock Has Average Price Target of $18.75
Kalaris Therapeutics Inc. (NASDAQ:KLRS) Receives $18.75 Average Target Price from Analysts
Kalaris Reports Second Quarter 2026 Financial Results and Provides Business Updates
Kalaris Therapeutics (NASDAQ:KLRS) Shares Up 15.4% – Here’s What Happened
Kalaris Therapeutics Reports Positive TH103 Phase 1a SAD Results from Expanded Neovascular AMD Cohorts
Recent Insider Trades
| Name | Type | Shares | Price | Date |
|---|---|---|---|---|
| Vandekop Amy O'Leary | A-Award | 10,000 | $4.10 | 2026-08-27 |
| KEATING LAURIE | A-Award | 18,000 | $3.51 | 2026-08-01 |
| KEATING LAURIE | 0 | — | 2026-08-01 | |
| Vandekop Amy O'Leary | 0 | — | 2026-07-27 | |
| Vandekop Amy O'Leary | 27,415 | $7.31 | 2026-07-27 |